[Contrykal as antifibrinolytic agent in obstetrics and gynecology].
D000307:Adrenal Gland Diseases / Q000628:therapy; D000328:Adult; D000347:Afibrinogenemia / Q000188:drug therapy*; D062365:Aminobenzoates / Q000627:therapeutic use; D000614:Aminocaproates / Q000627:therapeutic use; D000653:Amniotic Fluid / Q000201:enzymology; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D007611:Aprotinin / Q000627:therapeutic use; D004731:Endotoxins; D005260:Female; D005340:Fibrinogen / Q000627:therapeutic use; D005342:Fibrinolysis; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D010048:Ovarian Cysts / Q000628:therapy; D010920:Placenta / Q000201:enzymology; D006473:Postpartum Hemorrhage / Q000188:drug therapy*; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy*; D011480:Protease Inhibitors; D014592:Uterine Hemorrhage / Q000188:drug therapy*; D014594:Uterine Neoplasms / Q000628:therapy; D014599:Uterus / Q000201:enzymology
D062365:Aminobenzoates; D000614:Aminocaproates; D000933:Antifibrinolytic Agents; D004731:Endotoxins; D011480:Protease Inhibitors; D005340:Fibrinogen; D006493:Heparin; D007611:Aprotinin
Contrykal alsFibrinolysehemmstoff in der Gynäkologie und Geburtshilfe.